You are here

Clinical Trials: Heart Attack

Each Clinical Trial will open in a new browser window or tab.

Return to Clinical Trials Page

Posted: Wednesday, October 6, 2021 - 12:00
Condition:   Chronic Ischemic Left Ventricular Dysfunction
Interventions:   Drug: Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells;   Drug: Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells;   Drug: Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells
Sponsor:   Joseph C. Wu
Not yet recruiting
Posted: Tuesday, September 14, 2021 - 12:00
Conditions:   Myocardial Infarction, Acute;   Myocardial Infarction First;   Myocardial Infarction, Anterior Wall;   Cardiac Remodeling, Ventricular;   STEMI;   Regenerative Medicine;   Heart Failure
Interventions:   Biological: Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs);   Other: Conventional Treatment
Sponsors:   Shiraz University of Medical Sciences;   National Institute of Medical Research Development (NIMAD), Iran;   Cell Tech Pharmed Company, Iran
Recruiting
Posted: Friday, June 25, 2021 - 12:00
Conditions:   Myocardial Ischemia;   Ventricular Dysfunction, Left
Intervention:   Biological: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells
Sponsor:   Shanghai East Hospital
Recruiting
Posted: Monday, March 1, 2021 - 12:00
Conditions:   Diabetes Mellitus;   Ischemic Heart Disease
Interventions:   Drug: 100 million Allogeneic Mesenchymal Human Stem Cells;   Other: Placebo
Sponsors:   Joshua M Hare;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting
Posted: Thursday, January 28, 2021 - 12:00
Conditions:   Myocardial Infarction;   Heart Diseases
Intervention:   Device: Heart patch seeded with autologous cardiomyocytes and amnion epithelial stem cells
Sponsor:   Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
Not yet recruiting
Posted: Wednesday, September 16, 2020 - 12:00
Condition:   Coronary Artery Disease
Intervention:   Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS
Sponsors:   Navy General Hospital, Beijing;   Chinese PLA General Hospital;   Peking University Third Hospital;   Peking Union Medical College Hospital;   Xijing Hospital
Not yet recruiting
Posted: Wednesday, September 16, 2020 - 12:00
Condition:   Acute Myocardial Infarction
Interventions:   Biological: Intravenous infusion placebo;   Biological: Intravenous infusion WJMSCs
Sponsors:   Navy General Hospital, Beijing;   Peking University Third Hospital;   Peking Union Medical College Hospital;   Xijing Hospital;   Chinese PLA General Hospital
Not yet recruiting
Posted: Wednesday, July 22, 2020 - 12:00
Condition:   Severe COVID-19 Disease
Interventions:   Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19;   Other: Placebo
Sponsors:   Rapa Therapeutics LLC;   Hackensack Meridian Health
Not yet recruiting
Posted: Thursday, May 14, 2020 - 12:00
Condition:   Ischemia Reperfusion Injury
Intervention:   Drug: Allogeneic adipose derived mesenchymal stem cells
Sponsor:   Tambi Jarmi
Not yet recruiting
Posted: Thursday, April 9, 2020 - 12:00
Condition:   Acute Myocardial Infarction
Intervention:   Biological: Mesenchymal Stem Cells
Sponsor:   PT. Prodia Stem Cell Indonesia
Recruiting

Pages